ASH 2020 | Reduced-intensity induction + dasatinib vs hyperCVAD + TKIs in PH+ ALL
Mark Levis
• 3 Dec 2020
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the use of reduced-intensity induction with dasatinib, vincristine and dexamethasone, prior to allogeneic bone marrow transplant (alloBMT) in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Previous studies have shown that reduced-intensity induction with imatinib, a TKI, gives comparable outcomes and fewer induction-related deaths than hyperCVAD with imatinib. Additionally, dasatinib has been demonstrated to improve trial outcomes over imatinib, advocating this combination. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
